ChemotherapyDifferent
drugs are used for treating lung cancers. Just like weed killers kill
weeds and not the grass, or antibiotics kill bacteria and not us,
the chemotherapy drugs are aimed at attacking rapidly dividing cells
as are present in cancers and not normal body cells.
|
![]() |
Chemotherapy involves giving drugs which kill the cancer cells by attacking the dividing cells at different stages of the cell cycle.
Drugs commonly used are:
Adverse Effects of the Chemotherapy:
Because these agents are very powerful, they can have effects on the body where other rapidly dividing cells occur:The effects of chemotherapy vary with the doses used and the combinations used. If given with radiation to the chest, chemotherapy may be given on week 1 and week 5 of, for example, a 6 week course of radiation treatment. If one likens chemotherapy to a weed killer that kills weeds and not the grass, one can understand that sometimes the grass ( normal body cells ) is affected by the weed killer being sprayed all over the area. Given time most of this effect corrects itself. On occasions a drug to stimulate bone marrow (Gm CSF - granulocyte, monocyte, colony stimulating factor) is used, but not all the time.
Chemotherapy effectiveness can be affected by several mechanisms:
The
chemotherapy drugs have a variety of targets, however they cause disruption
in some normal cellular processes which are so dramatic that the cell
must either repair itself quickly or initiate its own destruction (apoptosis).
In apoptosis the cell shrinks and condenses, fragmenting into multiple
membrane-bound bodies which are engulfed by surrounding cells without
inflammation or damage to the surrounding tissues. At a biochemical level
apoptosis involves fragmentation of nuclear DNA.
Aims of treatment must be clearly discussed from the beginning as to whether the lung cancer can be cured or can only be palliated (ie. growth temporarily halted). Combinations of drugs are usually employed and multiple cycles are used to kill as many cells as possible. without life threatening toxicity or development of resistance.
Age is not necessarily a factor in whether to treat or not, but rather age related organ dysfunction such as bone marrow reserve and renal function may increase risks of toxicity.
The performance status usually correlates with the response (ie. if a patient is quite fit despite the cancer, then the results are better). If patients are malnourished with low serum proteins, the binding of some drugs is affected adversley. Drug doses are adjusted for actual and predicted body weight, cardiac function, liver function and blood counts.
It
is common to evaluate patients after 2 or 3 cycles of treatment to determine
the treatment effectiveness. If a response is seen, then therapy is usually
given for several cycles beyond that for the complete response. If tumour
progression is noted, therapy is not continued. For patients with stable
disease,an assessment of drug toxicity is important. If therapy is tolerable,
a decision to continue treatment is reasonable with the understanding
that eventual disease progression will occur.